#3-65E. Delabeling Antibiotic Allergies: The New ESCMID Guidelines (Clin Microbiol Infect, 2026)

How often does a dubious "penicillin allergy" label force you to prescribe suboptimal second-line antibiotics, thereby fueling antimicrobial resistance? The 2026 ESCMID Clinical Guidelines address this critical stewardship challenge by providing a structured, risk-stratification framework designed specifically for non-allergist clinicians to evaluate and manage reported antibiotic allergies. The guidelines categorize patients into very low, low, and high-risk groups, recommending that patients with non-severe reactions occurring more than five years ago be classified as "low risk." This pivotal shift allows non-specialists to safely perform direct drug challenges or delabeling without prior skin testing, significantly expanding access to first-line beta-lactams. However, clinicians must critically note that this document serves as an "umbrella guideline" synthesizing existing national protocols; consequently, much of the underlying evidence is observational with low GRADE quality, and the five-year cutoff is a pragmatic consensus rather than a definitive biological threshold. Nevertheless, for physicians navigating the complexities of antimicrobial stewardship, adopting these algorithms offers a vital, evidence-based pathway to optimize clinical outcomes and reduce the collateral damage of unnecessary broad-spectrum prescribing.

Citation: Joean O, et al. ESCMID Clinical Guidelines on the Evaluation and Management of a Reported Antibiotic Allergy. Clinical Microbiology and Infection. 2026. DOI: https://doi.org/10.1016/j.cmi.2026.02.011

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.